GI Colorectal / Rectal Cancer (CRC)

Localized

- Colon
  - Adjuvant
  - Neoadjuvant / Adjuvant

- Anal (Squamous Cell)
  - Adjuvant
  - Neoadjuvant / Adjuvant

- Rectal
  - Adjuvant
  - Neoadjuvant / Adjuvant

Non-Intervention CRC

- IRB# 21658 BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
- IRB# 18000 EXERCISING TOGETHER for Couples Coping with Cancer
- IRB# 22474 Establishing a ctDNA biomarker to improve organ preserving strategies in patients with rectal cancer
- IRB# 22465 A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
- IRB# 22189 A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/ Bevacizumab for Metastatic Colorectal Cancer
- IRB# 21972 A Phase 3 Study to Evaluate the Efficacy and Safety of Olaparib Alone Or In Combination With Bevacizumab Compared To Bevacizumab With 5-Fu In Participants With Unresectable Or Metastatic Colorectal Cancer Who Have Not Progressed Following First-Line Induction Of FOLFOX With Bevacizumab

Metastatic Anal

1st Line

- IRB# 21972

2nd Line

3rd Line

Beyond 3rd Line HER2+

No Trials Currently Available

CROSS-DISEASE TRIALS:

- IRB# TBD EAY131 (MATCH)

- IRB# 19576 Phase 1B Study to Assess the Safety of Neoadjuvant TAS-102 (Lonsurf) with Concurrent Radiation in Previously Untreated Resectable Stage II and Stage III Rectal Cancer

- IRB# 20980 Immunotherapy during neoadjuvant therapy for rectal cancer, a phase II randomized multi-center trial with and without APX005M, an anti-CD40 agonist

- IRB# 23240 A Phase 3 study of MK-4280A Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer

KEY

- Open to Enrollment
- In Development
- Enrollment on Hold

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result